Amarantus Bioscience Holdings Inc
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprieta… Read more
Amarantus Bioscience Holdings Inc (AMBS) - Net Assets
Latest net assets as of March 2023: $-24.70 Million USD
Based on the latest financial reports, Amarantus Bioscience Holdings Inc (AMBS) has net assets worth $-24.70 Million USD as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.22 Million) and total liabilities ($34.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-24.70 Million |
| % of Total Assets | -241.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Amarantus Bioscience Holdings Inc - Net Assets Trend (2008–2022)
This chart illustrates how Amarantus Bioscience Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amarantus Bioscience Holdings Inc (2008–2022)
The table below shows the annual net assets of Amarantus Bioscience Holdings Inc from 2008 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-24.67 Million | -23.78% |
| 2021-12-31 | $-19.93 Million | -110.11% |
| 2020-12-31 | $-9.48 Million | -5.89% |
| 2019-12-31 | $-8.96 Million | +67.91% |
| 2018-12-31 | $-27.90 Million | -54.88% |
| 2017-12-31 | $-18.02 Million | -15.64% |
| 2016-12-31 | $-15.58 Million | -79.33% |
| 2015-12-31 | $-8.69 Million | -113.41% |
| 2014-12-31 | $-4.07 Million | +45.86% |
| 2013-12-31 | $-7.52 Million | -113.14% |
| 2012-12-31 | $-3.53 Million | -5.31% |
| 2011-12-31 | $-3.35 Million | -4375.18% |
| 2010-12-31 | $-74.86K | -359.44% |
| 2009-12-31 | $-16.29K | -9151.67% |
| 2008-12-31 | $180.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amarantus Bioscience Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10644720400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $293.38K | % |
| Other Comprehensive Income | $-293.38K | % |
| Other Components | $81.81 Million | % |
| Total Equity | $-24.67 Million | 100.00% |
Amarantus Bioscience Holdings Inc Competitors by Market Cap
The table below lists competitors of Amarantus Bioscience Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
U-Swirl Inc
PINK:SWRL
|
$4.62 |
|
BARON OIL
BE:GHA
|
$4.62 |
|
Gold And Gemstone
PINK:GGSM
|
$4.63 |
|
Golden Triangle Ventures Inc
PINK:GTVH
|
$4.65 |
|
KYN Capital Group Inc
PINK:KYNC
|
$4.62 |
|
Itokk Inc
PINK:IKTO
|
$4.62 |
|
SPO Global Inc
PINK:SPOM
|
$4.60 |
|
Sentry Technology Corp
PINK:SKVY
|
$4.54 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amarantus Bioscience Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -19,926,048 to -24,665,304, a change of -4,739,256.
- Net loss of 4,762,000 reduced equity.
- Other comprehensive income decreased equity by 11,450.
- Other factors increased equity by 34,194.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.76 Million | -19.31% |
| Other Comprehensive Income | $-11.45K | -0.05% |
| Other Changes | $34.19K | +0.14% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Amarantus Bioscience Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $0.00 | $0.00 | x |
| 2009-12-31 | $-0.01 | $0.00 | x |
| 2010-12-31 | $-0.04 | $0.00 | x |
| 2011-12-31 | $-9.54 | $0.00 | x |
| 2012-12-31 | $-3.76 | $0.00 | x |
| 2013-12-31 | $-2.50 | $0.00 | x |
| 2014-12-31 | $-0.83 | $0.00 | x |
| 2015-12-31 | $-0.98 | $0.00 | x |
| 2016-12-31 | $-0.21 | $0.00 | x |
| 2017-12-31 | $-0.26 | $0.00 | x |
| 2018-12-31 | $-0.12 | $0.00 | x |
| 2019-12-31 | $-0.03 | $0.00 | x |
| 2020-12-31 | $-0.03 | $0.00 | x |
| 2021-12-31 | $-0.04 | $0.00 | x |
| 2022-12-31 | $-0.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amarantus Bioscience Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4995.23%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-847.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -12708.89% | -16340.00% | 0.03x | 26.81x | $-22.89K |
| 2009 | 0.00% | -1660.10% | 0.26x | 0.00x | $-15.22K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-51.08K |
| 2011 | 0.00% | -1985.80% | 0.63x | 0.00x | $-4.11 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.78 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.38 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-26.87 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.35 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.02 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.64 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.79 Million |
| 2019 | 0.00% | 91.88% | 0.81x | 0.00x | $19.27 Million |
| 2020 | 0.00% | -840.70% | 0.00x | 0.00x | $320.36K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.20 Million |
| 2022 | 0.00% | -4995.23% | 0.01x | 0.00x | $-2.30 Million |
Industry Comparison
This section compares Amarantus Bioscience Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amarantus Bioscience Holdings Inc (AMBS) | $-24.70 Million | -12708.89% | N/A | $4.62 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |